Intra-tracheal challenges with antigen (OVA) or rmIL-13 induce lung inflammation, bronchial hyperreactivity (BHR) and mucus in mice as independent events (Singer et al, Am. J. Respir. Cell Mol. Biol. 2002, 26, 74-84), largely mediated by leukotrienes (LT). We have previously shown that LTC4 was released 15 min. after Ova, and we show here that it induces the expression of MCP-1, MCP-5, and KC in the lungs, as well as IL-13 mRNA s . Instilled i.t., these chemokines induced BHR and mucus accumulation, which were inhibited by the 5-LO inhibitor zileuton and by the Cys-LT-ra MK-571, suggesting a mediation by cysteinyl-leukotrienes.
Introduction
Different mediators, including cytokines (1,2,3,4,5), chemokines (6, 7) , leukotrienes (LT) and growth factors can induce the asthma phenotype in mice, with bronchopulmonary hyperresponsiveness (BHR), inflammation, and mucus overproduction (5, 8, 9, 10, 11) , but the underlying mechanisms remain unclear (15) . Murine models of lung allergy are widely used to unravel those mechanisms, and much attention has been devoted to the mediator role of IL-13 which, upon administration into the airways, duplicates the characteristic features of asthma (1, 2, 3, 4, 5, 8, 9, 10, 16, 17) . We demonstrated that neither inflammation (3,4) nor a Th1/Th2 inbalance (3), are required for BHR and for mucus accumulation. Because the effects of rmIL-13 are inhibited by dexamethasone and, accordingly, may involve secondary mediators (3), we investigated the role of LT as potential mediators of the effects of Ova and of rmIL-13 on inflammation, BHR, mucus accumulation and lung remodelling (5, 8, 9) . Since some chemokines also exert intense proinflammatory effects reminiscent of asthma, we extended our investigations to chemokines which are expressed and involved in those models (6, 7, 18) . MCP-1, MCP-5 and KC were selected, because they were expressed after Ova, rmIL-13 or LT challenges and, once instilled into the trachea, induced BHR and mucus accumulation, more than did eotaxin, RANTES and MIP-1α. Our results point out a major role for cysteinyl-LT (Cys-LT) in mediating the pulmonary effects of the relevant chemokines. The latter, IL-13 and LT cooperate in inducing the asthma phenotype. In addition, because of suggestions that activation of the EGF receptor (EGFR) (19, 20, 21, 22, 23) may trigger the final common pathway leading to BHR and to mucus production, its expression was also studied. Our results indicate that the different mediators, which have been considered individually to account for the phenotype observed, interact positively, reinforcing their respective release. Those positive feedback loops may explain why drugs which interfere specifically with single receptors or that suppress selectively the production of a given mediator show some, but limited therapeutic effectiveness, and suggest that new therapeutic targets should down-regulate the common pathway.
Materials and methods

Animals, immunization and materials
Male BP2 mice (Centre d'Elevage R. Janvier, France), aged 6-7 weeks, were immunized (or not) subcutaneously twice at a week interval with 0.4 mL 0,9% NaCl containing 1 µg of ovalbumin (Ova, Immunobiologicals, Lisle, IL) and 1,6 mg of aluminium hydroxide (Merck, Darmstadt, Germany). One week after the second immunization, i.e., at day 14, mice were anaesthetized with xylazine 12% (20 mg/kg) and ketamine 500 (45 mg/kg) (both from Sigma, St Louis, MO) and groups of 5 were instilled intratracheally (i.t.) with Ova (10 µg), or rmIL-13 (4 µg), or chemokines (1 µg/day for 3 days), or LTC4 (1µg/mice). Rm-IL13 was kindly provided by Dr. A. Minty (Sanofi Elf Biorecherches, Labège, France) and diluted in 50 µl of endotoxin-free 0,9% NaCl (saline); LTC4 was from Cayman Chemical, (Ann Arbor, MI). The recombinant murine (rm) chemokines rmMCP-1, rmMCP-5, rmKC, were from Immugenex Corp. (Los Angeles, CA).
With a group of saline and of challenged animals (n=5), groups of 5 mice were challenged and treated separately with different drugs: the specific 
Evaluation of bronchopulmonary hyperreactivity (BHR)
Basal resistance of the airways and BHR were assessed in unrestrained conscious animals by barometric plethysmography (Buxco Electronics
Inc., Troy, NY). Bronchial reactivity was evaluated using noncumulative methacholine challenges (3,5,28). Briefly, mice were placed in a Buxco chamber and respiratory parameters were measured after methacholine aerosol inhalation for 90 sec. at 60 mM. Resistance was calculated according to the manufacturer's recommendations as: Penh (enhanced pause) = (expiratory time /relaxation time) -1 ) x peak expectory flow / peak inspiratory flow.
For the graphic representation, cumulated areas under the curve were used.
Bronchoalveolar lavage fluid (BALF)
Mice were anesthetized i. 
Determination of Cys-LT and LTB4 in the BALF by Elisa
Fresh cell-free BALF, or nitrogen congelated cell-free BALF kept for less than 72 hours were used. In some samples, a known quantity of the specific LT (LTC4 or LTB4 used as internal standard) was added before congelation to verify the integrity of the samples during time. The quantification (pg/ml) was achieved by EIA according to the manufacturer's instructions (Enzyme immunoassay kit for Cys-LT or for LTB4 ; Cayman Chemicals, Ann Arbor, MI) as compared to a standard curve for LTB4 or Cys-LT.
Quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction):
Lungs were isolated and washed with saline via the pulmonary artery.
Dispersion was performed with an Ultraturrax (T25 Janke and Kunkel, IKA R -Labortechnik, Germany) for 30 sec. in the RTL buffer from the RNeasy Mini kit (Quiagen, Hilden, Germany) used for RNA s extraction.
Intron-differential RT-PCR was performed for lungs, using specific primers for MCP-1, 5' TGCTACTCATTCACCAGCAAG 3' GGGAGAGCATAGCCCTCGTAGAT.
The cDNA s were synthetized, and PCR performed as described (3,5), using 63°C for annealing. Standards were prepared as described (29) when cloned-plasmids were available, or the specific PCR product were checked on an agarose gel and purified as described (5). The copy number was calculated according to the OD, then the purified DNA was serially diluted to obtain the appropriate standard containing 0 to 1 million of copies. The copy number of the sample was calculated relatively to the standard, after PCR amplification on the LightCycler System (Roche Molecular Biochemicals, Mannheim, Germany), for the chemokine and for ß-actin independently, on the same cDNA s preparation. The results are given as a ratio chemokine/ß-actin copies.
Histology
The lungs were flushed to remove blood, then inflated with OCT (Optimum Cutting Temperature medium (Sakura Finetck, Torrance, CA), half diluted in saline. For paraffin inclusion, the lungs were immersed in 10% formaldehyde in PBS overnight at 4°C, and processed to paraffin wax. 5 µm sections were stained with Periodic acid Schiff/haematoxilin for mucins. To assess the frequency of staining, the ratio stained cells/total cells was evaluated by counting the epithelial cells under the microscope with a grid as described (3) and results are given in %.
Statistical analysis
All results are presented as means ± standard deviation (n=5).
Significance levels were calculated using one way ANOVA followed by Scheffe's test, using the SPSS 6.1 software (* significance between data with a threshold of p< 0.05, n=5).
Results
We recently demonstrated that LT mediate BHR and mucus overproduction in the mouse airways, after provocations with Ova (8) or with rmIL-13 (3,5). In order to investigate the interactions between chemokines and LT for inducing those changes, we first studied mRNA s expression for MCP-1, MCP-5, and KC, which are chemokines involved in allergy. Since
Cys-LT are the first LT released, as early as 10 min. after challenge (5), we also evaluated chemokine synthesis and IL-13 expression after the i.t.
instillation of LTC4. In addition, because these chemokines were expressed after challenge with Ova, rmIL-13 or LTC4, they were instilled directly into the airways, and the release of LT as well as their effects on BHR and mucus production were studied. Then, in order to understand the mediator role of LT after chemokine challenge, the 5-LO inhibitor zileuton and the Cys-LT receptor antagonist MK-571 were used against BHR, MUC genes and mucus induction. Finally, since EGFR may be involved in signalling pathway for BHR and mucus, its expression was studied.
Ova or rmIL-13 challenges induce chemokines mRNA s expression.
After Ova instillation, a time-dependent progressive induction of mRNA s for MCP-1 ( Figure 1A ) was observed. A high level of expression for MCP-hours and then decreased. A high level of expression for KC mRNA s was observed after 15 min, then it decreased, to increase again progressively from 3 to 48 hours ( Figure 1C ).
After the instillation of rmIL-13, the expression of chemokines was constant at all time points (Figure 1D, 1E, 1F ), but a slight reduction was observed at 1-3 hours for MCP-1 and KC ( Figure 1D, 1F) .
LTC4 challenge induces the expression of mRNA s for MCP-1, MCP-5, KC, and IL-13
The i.t. instillation of LTC4 also induced the expression of mRNA s for chemokines, with an early peak at 15 min. for MCP-1, MCP-5, and a late one at 72h (Figure 2A, B) , or a more progressive increase of KC ( Figure   2C ). LTC4 induced IL-13 mRNA s at all time points ( Figure 2D ).
Chemokines induce leukotriene release into the BALF
The release of Cys-LT in the BALF after challenge with MCP-1, MCP-5 or KC peaked at 1 hour, then decreased progressively until a plateau was 
Chemokines induce the expression of MUC-genes mRNA s
The expression of the MUC-1 gene was stable after the different challenges, confirming that it is constitutive ( Figure 6A ). MUC-2 mRNA s were induced from 24 to 72 hours after rmIL-13 and the chemokines MCP-1, MCP-5 and KC, but poorly so after Ova ( Figure 6B at 24 hours).
MUC-5AC mRNA s were intensively induced in all cases ( Figure 6C at 24 hours). 
EGF Receptor (EGFR) expression is increased after
Chemokines cooperate with leukotrienes and IL-13 to induce BHR and mucus
The potential role of chemokines for mediating inflammation is largely documented (18,23). Our concept is that C-C chemokines (MCP-1, and MCP-5 (6,30,31,32)), and C-X-C chemokines such as KC (33) , which are expressed after Ova, rmIL-13 or LTC4 challenges in mice (Figure 1 ), induce at least part of their effects, such as BHR and mucus production, via the Cys-LT, since their inhibition or antagonism abolished these effects.
LT are associated to , or induce cytokines and chemokines in others models, for instance in mast cells (34) . They potentiate chemoattraction by eotaxin (35) . It is possibly implicated in the latter's effects, suggesting another positive loop of regulation. MCP-5 also induced LT release and therefore joins the loop described in Figure 8 .
KC (33) is the murine counterpart of human Gro-alpha (IL-8 family, KC/GRO 65% sequence identity, receptor CXCR1). In addition to its recognized implication in inflammation, we demonstrate here that KC induces a strong BHR and mucus accumulation in the airways, also mediated by LT, since they were inhibited by zileuton and MK-571. KC was also induced after rmIL-13 and after Ova, and probably mediates a part of their effect. Moreover, KC induced LT release into the BALF, and IL-13 mRNA s in the lungs. Since IL-13 induced KC, it joins the loop described in Figure 8 for MCP-1 and MCP-5.
The coordinated action of the different mediators perpetuates and amplifies the asthma-like phenotype in mice
Biological loops, leading to increased basal levels of the relevant mediators, seem to emerge from this analysis (3,11,18,30 ). Their coordinated effects should lead to signal transduction for BHR (via LT, (5, 7, 11, 18, 30, 35) , and mucus accumulation, in addition to inflammation.
Even single molecules (MCP-1, MCP-5, KC, IL-13 in vivo), were able to induce an effect. Indeed, high levels of the relevant mediators, expressed at the same time, are observed in mice models (10, 11, 30) as well as in asthmatic patients (18).
Other biological loops have been suggested, in which chemokines induce their further production via GPC receptors, as «an autocrine regulatory mechanism which enhances chemokines' effects » (23).
Regulatory molecules such as IFN-γ, which down-regulates mucin expression (36) , may also interfere with IL-13 (37) . However, this downregulation may fail under some conditions, since IFN-γ can induce MCP-1 (38,39) which promotes BHR and mucus, as well as Cys-LT1 receptor expression and BHR (40) . This may explain why BHR and mucus accumulation have a propensity to amplify, without efficient downregulation.
Which pathway links LT, IL-13 and chemokines ?
Different receptors are involved in the effects of the mediators we studied 
